Valneva's Stock Jumps 4.47% Amid Extreme Oversold Territory

Current Market Position and Technical Indicators

Valneva's stock price is currently well below its main moving averages: the 50-day moving average (MM50) is at 4.21 euros and the 200-day moving average (MM200) at 3.87 euros, representing respective gaps of 30% and 24% from today's price. This setup indicates a deeply entrenched downward trend that has been in place for several weeks. The Relative Strength Index (RSI), a momentum indicator that measures the velocity and magnitude of price movements, stands at 27, well below the generally considered oversold threshold of 30. It is in this tense technical context that today's rise occurs: a mechanical rebound following an intense decline phase, with the stock finding support around 2.76 euros. The CAC 40 is up 2.12% during the session, which helps lift the entire Parisian stock market, including biotechnological stocks. The SBF 120 shows a similar dynamic, up 2.14%. In the healthcare sector, Sanofi is up 0.42% and UCB by 3.17%, indicating a renewed interest in the European pharmaceutical sector at the start of the month.

Financial Calendar and Upcoming Events

Valneva's financial calendar includes several key dates that could influence the stock in the coming weeks. The laboratory will publish its first-quarter results on May 7, a crucial moment to assess the commercial trajectory of its vaccines and the control of its operational expenses. The annual general meeting, scheduled for June 1, might also provide details on the group's medium-term strategy. Over the past year, the stock's performance remains negative at -4.6%, while the decline over three months reaches -20.76%. The stock's negative beta of -0.71 indicates an inverse correlation with the market, meaning that Valneva tends to move in the opposite direction of the benchmark index. This atypical profile deserves particular attention in a context of high market stress: the VIX, a volatility barometer, stood at 31.05 points at the close of Friday, March 27, up more than 13% from the previous day, reflecting an extremely tense level. The most significant resistance is at 5.08 euros, more than 72% above the current price, illustrating the extent of the journey for the stock to return to its levels at the beginning of the year.